Previous studies have shown that CXCL10 concentrations in cerebrospinal fluid (CSF) are positively correlated with the severity of cognitive impairment in AD patients [67, 68], while CXCR3-deficient mice exhibit significant reductions in plaque burden and Aβ levels [69], suggesting that the activation of CXCR3 pathways has negative implications for AD. This evidence concerns the gene CXCL10 and Alzheimer disease.